SpyGlass Pharma

SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.